So cool to see these come out. I'm clicking through for holiday reading. Nice work Ruxandra Teslo 🧬 Willy Martin Landray Stuart Buck Josh Morrison Alastair Fraser-Urquhart Mark Webb Enlli McAleese Frank S. David J Allison Foss & Michael Lingzhi Li

Imagine a world where flu is no longer a constant, unpredictable threat. My latest piece with Ryan Duncombe  on the quest for developing universal flu vaccines now live Asimov Press From the looming threat of H5N1 to the yearly burden of winter flu, why are we still stuck in a

PEPFAR is one of the most popular, bipartisan US foreign aid programs. The State Department says it has saved 25million lives, but there isn't much public, independent verification. Last week I invited some friends to a weekend hackatjon to see if PEPFAR's numbers held up.

FDA, RIF's, and User Fees Explained in today's SPECIAL EDITION of FDA Matters: The Grossman FDA Report: fdamatters.com! ------------------------------ #FDA #FDAMatters #TheGrossmanFDAReport #FDAreform #FDApolicy #FDAregulations #FutureofFDA #FDARIF #RIF #UserFees

An invaluable resource for better understanding the intricacies of the FDA

Curious what happened to FDA's queue in 1992? Read on: substack.com/@foodanddrugsf…

The latest from FDAMatters — The Grossman FDA Report: Chesterton’s Fence: The Meaning of Deregulation & Other Thoughts About FDA Read it here: fdamatters.com --- #FDA #FDAMatters #TheGrossmanFDAReport #FDApolicy #rif #userfees #deregulation #cspi #politico

The application deadline to become a Patient Experience (PX) Partner for our RAPID program is 4/24. As PX Partners, patient advocacy groups will collaborate with technical teams to advance patient-centered solutions that accelerate rare disease diagnosis. ow.ly/Ik1i50Vlov3

GHTC sat down with Dr. Iain Barton from Health 4 Development and Vizuri Health Dynamics to shed some light on opportunities for coordination and alignment with WHO's prequalification (PQ) program.

As the U.S. FDA faces significant staffing reductions, there could be ripple effects for US companies and leadership in the biomedical space, as well as for other countries that depend on the FDA's leadership to enable access to essential health technologies. 1Day Sooner

As US FDA faces staffing reductions that threaten US innovation and global health systems that depend on it, Congress has an opportunity with the Prescription Drug User Fee Act reauthorization to invest in the FDA’s workforce and secure the agency's ability to lead. 1Day Sooner

Recent staffing cuts at the U.S. FDA have prompted concerns about potential impacts on US leadership in the biomedical space, hampering the FDA’s status as the gold standard globally and disadvantaging US-based manufacturers of products for diseases endemic in LMICs. 1Day Sooner

Check out our interactive primer which unpacks the complex web of multilateral organizations 🏛️🌐 and breaks down how each contributes to the research, development, and delivery of #GlobalHealth technologies. 💉 💊 🔬

Thrilled to be collaborating with Federation of American Scientists🔬 on this event! Looking forward to hearing insights from Sandeep Patel , J.P. Chretien and Liang Zhao on this timely topic

Excited to be co-hosting this event with Federation of American Scientists🔬 next week—should be a great discussion! Register here: us06web.zoom.us/webinar/regist…

GHTC sat down with Dr. Benjamin Djoudalbaye (Benjamin Djoudalbaye), head of the African Medicines Agency (AMA) interim secretariat, to discuss what he envisions for AMA as an agency in the next five to ten years.

Excited to share what Usman and I have been thinking against the backdrop of where AI for science can unlock the most potential for serendipity and discovery. Introducing the 'Bacon Junction.' The most optimal zone that taps into the novel method of how models embed and

Congrats Gavriel and Karam Elabd ! worksinprogress.co/issue/the-deat…